Literature DB >> 18388157

The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.

W H Bos1, J Ursum, N de Vries, G M Bartelds, G J Wolbink, M T Nurmohamed, I E van der Horst-Bruinsma, R J van de Stadt, J B A Crusius, P P Tak, B A C Dijkmans, D van Schaardenburg.   

Abstract

OBJECTIVES: Patients presenting with both arthralgia and antibodies to cyclic citrullinated peptide (anti-CCP) have an increased risk of developing rheumatoid arthritis (RA). To further characterise this patient group and shed more light on its relationship with clinically manifest early arthritis and established RA, an immunogenetic and serological analysis was performed.
METHODS: In a group of 111 patients with anti-CCP-positive arthralgia, anti-CCP levels and shared epitope (SE) status were determined. Data were compared with 125 and 128 patients with anti-CCP-positive early arthritis and established RA respectively.
RESULTS: In patients with anti-CCP-positive arthralgia, the frequency of SE allele positivity is significantly lower when compared with anti-CCP-positive early arthritis and established RA (58% vs 80%, and 58% vs 92%, respectively, both p<0.001). Median anti-CCP levels were higher in the group of patients with SE-positive arthralgia compared with the group of patients with SE-negative arthralgia (p = 0.02). Median anti-CCP levels were similar in the groups of patients with SE-positive arthralgia and arthritis.
CONCLUSIONS: The lower frequency of SE positivity in patients with arthralgia compared with patients with RA indicates that, compared with patients who were SE positive, patients who were SE negative as a group go through a longer arthralgia phase, or alternatively have a lower risk for transition from anti-CCP positive arthralgia to RA. Furthermore, the present results suggest that in this early stage the effect of the SE on disease risk may be mediated through higher anti-CCP levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388157     DOI: 10.1136/ard.2008.089953

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Predicting and preventing the development of rheumatoid arthritis.

Authors:  Karim Raza; Lars Klareskog; V Michael Holers
Journal:  Rheumatology (Oxford)       Date:  2015-07-29       Impact factor: 7.580

Review 2.  Environmental and gene-environment interactions and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Kevin Deane
Journal:  Rheum Dis Clin North Am       Date:  2012-05-30       Impact factor: 2.670

3.  Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis.

Authors:  Shunsuke Mori; Jun Hirose; Kensuke Yonemura
Journal:  Clin Rheumatol       Date:  2010-04-11       Impact factor: 2.980

Review 4.  Genetic and environmental risk factors for rheumatoid arthritis.

Authors:  Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-09-18       Impact factor: 4.098

Review 5.  The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA.

Authors:  Annie Yarwood; Tom W J Huizinga; Jane Worthington
Journal:  Rheumatology (Oxford)       Date:  2014-09-18       Impact factor: 7.580

6.  Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.

Authors:  Bogdan Kolarz; Maria Majdan; Magdalena Dryglewska; Dorota Darmochwal-Kolarz
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

Review 7.  Pre-symptomatic autoimmunity in rheumatoid arthritis: when does the disease start?

Authors:  Alexander Tracy; Christopher D Buckley; Karim Raza
Journal:  Semin Immunopathol       Date:  2017-03-23       Impact factor: 9.623

8.  Association of human leukocyte antigen DRB1 with anti-cyclic citrullinated peptide autoantibodies in Saudi patients with rheumatoid arthritis.

Authors:  Abdullah Alrogy; Abduallah Dirar; Waleed Alrogy; Hana Fakhoury; Ali Hajeer
Journal:  Ann Saudi Med       Date:  2017 Jan-Feb       Impact factor: 1.526

Review 9.  Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.

Authors:  Fenne Wouters; Marc P Maurits; Laurette van Boheemen; Marloes Verstappen; Kulveer Mankia; Xanthe M E Matthijssen; Annemarie L Dorjée; Paul Emery; Rachel Knevel; Dirkjan van Schaardenburg; René E M Toes; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

10.  Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.

Authors:  Nicola Bizzaro; Elena Bartoloni; Gabriella Morozzi; Stefania Manganelli; Valeria Riccieri; Paola Sabatini; Matteo Filippini; Marilina Tampoia; Antonella Afeltra; Giandomenico Sebastiani; Claudia Alpini; Vittorio Bini; Onelia Bistoni; Alessia Alunno; Roberto Gerli
Journal:  Arthritis Res Ther       Date:  2013-01-22       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.